Clinical trials: Gastrointestinal Stromal Tumor
Small Size Gastrointestinal Stromal Tumors, GIST
RCT of EFTR Versus STER for GIST Treatment
Endoscopic resection has been increasing utilized as the treatment for small size gastrointestinal stromal tumors (GIST), of which the best resection method has not been identified.
- Trial name
- NCT07411118
- Testing
- Endoscopic full thickness resection (EFTR) / Exposed non-tunneling EFTR, Submucosal Tunneling Endoscopic Resection (STER) / Exposed tunneling EFTR
- Where
- 4 sites in China, Hong Kong and 2 more
- Volunteers
- 136 people
- Sponsor
- Chinese University of Hong Kong
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Gastrointestinal Stromal Tumor (GIST)
A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
The purpose of this study is to test the safety and tolerability of the combination of pexidartinib and MEK162. This study tests different doses of pexidartinib in combination with different doses of MEK162 to see which dose…
- Trial name
- NCT03158103
- Testing
- MEK162, Pexidartinib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastrointestinal Stromal Tumor
Surgery for Locally Unresectable Advanced GISTs Without Metastasis After Imatinib Therapy
Gastrointestinal stromal tumors (GISTs) are a form of sarcoma and the most common sarcoma tumors of the gastrointestinal tract. The limited clinical experience suggests that GIST patients may benefit from neo-adjuvant therapy…
- Trial name
- NCT01865565
- Where
- Taiwan
- Volunteers
- 51 people
- Sponsor
- Chang Gung Memorial Hospital
Gastrointestinal Neoplasms
A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib
The goal of this study is to evaluate the study drug velzatinib (GSK6042981 / IDRX-42) to see whether velzatinib can shrink or control tumors and is safe and tolerated in Japan participants with gastrointestinal tumors (GIST) who…
- Trial name
- NCT07689201
- Testing
- Velzatinib
- Where
- 3 sites in Japan
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Gastrointestinal Stromal Tumor(GIST)
Ripretinib Combined With Surgery in Advanced GIST That Have Failed Imatinib Therapy: A Multicenter,Observational Study
The objective of this observational study is to explore the efficacy and safety of ripretinib treatment combined with surgery in advanced gastrointestinal stromal tumors(GIST) after failure of imatinib therapy.
- Trial name
- NCT05354388
- Testing
- Resection surgery of gastrointestinal stromal tumor
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan Provincial People's Hospital
Liver Diseases, Liver Cancer
Liver Transplantation for Unresectable GIST Liver Metastases
Liver Transplantation for Unresectable GIST Liver Metastases
- Conditions
- Liver Diseases, Liver Cancer, Liver Metastases, Liver Neoplasms
- Trial name
- TRANSGIST (NCT04825470)
- Testing
- Liver Transplantation
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Hospital Universitario Virgen de la Arrixaca
Gastrointestinal Stromal Tumor of Stomach
Robotic Resection for Patients With Gastric Gastrointestinal Stromal Tumors: a Single-center Study
Patients with gastric gastrointestinal stromal tumors will receive robotic resection.
- Trial name
- NCT03238820
- Testing
- Robotic gastric gastrointestinal stromal tumors resection
- Where
- China
- Volunteers
- 50 people
- Sponsor
- JIANG Zhi-Wei
Soft-tissue Sarcoma, Gastrointestinal Stromal Tumors
Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWORK
Post-authorisation, multicentric, observational, retrospective and prospective study to assess quality of care of sarcoma patients in expert and non-expert centers by analysing correlation of quality items and outcomes such as…
- Conditions
- Soft-tissue Sarcoma, Gastrointestinal Stromal Tumors, Bone Sarcoma
- Trial name
- (SELNET) (NCT04181970)
- Testing
- Quality assessment
- Where
- 9 sites in Argentina, Brazil and 6 more
- Volunteers
- 5,000 people
- Sponsor
- Grupo Espanol de Investigacion en Sarcomas
Melanoma, Non-small Cell Lung Cancer
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
The goal of this clinical research study is to learn how PLX3397 and pembrolizumab work together to affect cancer cells. PLX3397 is designed to target the receptor for CSF1 (CSF1R).
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Gastrointestinal Stromal Tumor (GIST)
- Trial name
- NCT02452424
- Testing
- PLX3397, Pembrolizumab
- Where
- 12 sites in United States
- Volunteers
- 78 people
- Sponsor
- Daiichi Sankyo
Gastrointestinal Stromal Tumors
Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor
To evaluate the antitumor activity of SU011248 in advanced, imatinib mesylate-resistant gastrointestinal stromal tumor (GIST) when administered on a continuous daily dosing schedule
- Trial name
- NCT00137449
- Testing
- SU011248
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 60 people
- Sponsor
- Pfizer
Gastrointestinal Stromal Tumors (GIST), Neoplasms, Connective Tissue
A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
This study will assess the safety, efficacy, and pharmacokinetics of THE-630 in participants with advanced gastrointestinal stromal tumors (GIST).
- Conditions
- Gastrointestinal Stromal Tumors (GIST), Neoplasms, Connective Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type
- Trial name
- NCT05160168
- Testing
- THE-630
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Theseus Pharmaceuticals
Gastrointestinal Stromal Tumor
Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known which dose of imatinib mesylate is more effective in treating gastrointestinal stromal…
- Trial name
- NCT00685828
- Testing
- imatinib mesylate
- Volunteers
- 946 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
This is a research study to evaluate how the genetic makeup of Pancreatic Ductal Adenocarcinoma (PDAC) can affect the response to FDA-approved chemotherapy treatment, FOLFIRINOX, given before surgery to remove the tumor.
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Cancer of Pancreas, Pancreatic Cancer, Adult, Pancreas Adenocarcinoma
- Trial name
- NCT03977233
- Testing
- Oxaliplatin, Leucovorin, Irinotecan Hydrochloride
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Pancreatic Neoplasms
Correlation Between Elastic Modulus of Ultrasonic Shear Wave and Tumor Stromal Component in Pancreatic Cancer
Pancreatic cancer is a gastrointestinal tumor with a high degree of malignancy. Currently, there are many first-line chemotherapy regimens in clinical practice, but the individual selection of chemotherapy regimens has not been…
- Trial name
- NCT05187416
- Testing
- two-dimensional shear wave elastography
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Xijing Hospital
Gastrointestinal Stromal Tumors
Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients
The purpose of this study is to determine if escalating the dose of imatinib to keep the drug blood level at ≥ 1100 ng/ml leads to better outcomes for patients.
- Trial name
- NCT01031628
- Testing
- Imatinib mesylate
- Where
- 13 sites in United States
- Volunteers
- 5 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Gastro-intestinal Stromal Tumors
The GALLOP-11 Study
An observational, multicenter study will be performed. Regular 3-12 monthly follow-up by CT-scan will be compared to results of ctDNA analysis.
- Trial name
- NCT05178030
- Testing
- vena punction
- Where
- 5 sites in Netherlands
- Volunteers
- 243 people
- Sponsor
- University Medical Center Groningen
Gastrointestinal Stromal Tumors
A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore
To review the characteristics and treatment of gastrointestinal tumours at the two tertiary centres in Singapore
- Trial name
- NCT00718211
- Where
- Singapore
- Sponsor
- National University Hospital, Singapore
Gastrointestinal Stromal Tumor
Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors
A phase IIIb study of patients with gastrointestinal stromal tumors who have had progressive disease while on 400 mg imatinib. Patients will be randomly assigned to either sunitinib 37.5 mg daily or imatinib 800 mg daily.
- Trial name
- NCT00372567
- Testing
- sunitinib malate, imatinib mesylate
- Where
- 25 sites in United States, Germany and 5 more
- Volunteers
- 69 people
- Sponsor
- Pfizer
Maximum Tolerated Dose, GIST
Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST)
This is a single-arm, two cohort, open label phase I/II clinical trial studying the combination of oral imatinib 400 mg, once daily, and oral selinexor given once weekly (Cohort A); and single-agent oral selinexor 60 mg BIW…
- Conditions
- Maximum Tolerated Dose, GIST, Metastatic Adult Soft Tissue Sarcoma, Drug Toxicity
- Trial name
- SeliGIST (NCT04138381)
- Testing
- Selinexor, Imatinib
- Where
- 6 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Grupo Espanol de Investigacion en Sarcomas